Novartis AG Company Profile (NYSE:NVS)

About Novartis AG

Novartis AG logoNovartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: NVS
  • CUSIP:
Key Metrics:
  • Previous Close: $80.88
  • 50 Day Moving Average: $80.64
  • 200 Day Moving Average: $78.59
  • 52-Week Range: $69.90 - $95.11
  • Trailing P/E Ratio: 28.88
  • Foreward P/E Ratio: 15.77
  • P/E Growth: 2.78
  • Market Cap: $192.59B
  • Outstanding Shares: 2,381,221,000
  • Beta: 0.58
Profitability:
  • Net Margins: 13.84%
  • Return on Equity: 15.33%
  • Return on Assets: 8.66%
Debt:
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 0.90%
  • Quick Ratio: 0.65%
Additional Links:
Companies Related to Novartis AG:

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.13)
Consensus Price Target: $93.50 (15.60% upside)

Analysts' Ratings History for Novartis AG (NYSE:NVS)
Show:
DateFirmActionRatingPrice TargetDetails
9/20/2016Chardan CapitalInitiated CoverageBuy$95.00View Rating Details
9/13/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
8/25/2016ArgusReiterated RatingHoldView Rating Details
7/12/2016Bank of America Corp.Reiterated RatingHoldView Rating Details
5/24/2016Citigroup Inc.Reiterated RatingNeutralView Rating Details
5/13/2016Jefferies GroupReiterated RatingBuyView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldView Rating Details
4/22/2016Barclays PLCUpgradeUnderweight -> Equal WeightView Rating Details
4/14/2016Credit Suisse Group AGReiterated RatingHoldView Rating Details
4/12/2016Morgan StanleyDowngradeEqual Weight -> UnderweightView Rating Details
1/28/2016BNP ParibasDowngradeOutperform -> NeutralView Rating Details
1/7/2016Goldman Sachs Group Inc.Boost Price TargetNeutral$89.00 -> $92.00View Rating Details
11/23/2015VontobelDowngradeHoldView Rating Details
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00View Rating Details
10/28/2015Main First Bank AGDowngradeUnderperformView Rating Details
7/7/2015Oddo SecuritiesInitiated CoverageBuyView Rating Details
6/25/2015HSBCInitiated CoverageBuyView Rating Details
6/22/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
3/4/2015NatixisUpgradeNeutral -> BuyView Rating Details
1/5/2015Cowen and CompanyUpgradeMarket Perform -> Outperform$95.00 -> $105.00View Rating Details
11/13/2014Kepler Capital MarketsUpgradeHold -> BuyView Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Novartis AG (NYSE:NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.10$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.21$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
10/28/2014Q3$1.31$1.33$14.51 billion$14.70 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014$1.27$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novartis AG (NYSE:NVS)
Current Year EPS Consensus Estimate: $4.76 EPS
Next Year EPS Consensus Estimate: $5.13 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$1.17$1.18$1.17
Q2 20163$1.12$1.21$1.17
Q3 20161$1.19$1.19$1.19
Q4 20162$1.13$1.24$1.19
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novartis AG (NYSE:NVS)
Annual Dividend:$2.30
Dividend Yield:2.84%
Dividend Growth:2.40% (3 Year Average)
Payout Ratio:82.14% (Based on Trailing 12 Months of Earnings)
48.32% (Based on Current Year Consensus EPS Estimate)
44.83% (Based on Next Year Consensus EPS Estimate)

Dividend History for Novartis AG (NYSE:NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Novartis AG (NYSE:NVS)
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 9.78%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Novartis AG (NYSE:NVS)
DateHeadline
finance.yahoo.com logo10 Stocks John Rogers Keeps Buying (NYSE:NVS)
finance.yahoo.com - September 27 at 6:24 PM
finance.yahoo.com logoKite Pharma Reports Favorable Data from Lymphoma Study (NYSE:NVS)
finance.yahoo.com - September 27 at 11:05 AM
capitalcube.com logoETF’s with exposure to Novartis AG : September 26, 2016 (NYSE:NVS)
www.capitalcube.com - September 26 at 6:35 PM
finance.yahoo.com logoNovartis Ilaris Approved for Extended Use in Periodic Fever (NYSE:NVS)
finance.yahoo.com - September 26 at 11:11 AM
marketrealist.com logoWinning? We Review How Teva Dominates Generic Drug Space (NYSE:NVS)
marketrealist.com - September 26 at 11:11 AM
seekingalpha.com logoFDA OKs three new uses for Novartis' Ilaris - Seeking Alpha (NYSE:NVS)
seekingalpha.com - September 24 at 10:55 AM
finance.yahoo.com logoUPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure (NYSE:NVS)
finance.yahoo.com - September 23 at 11:13 AM
finance.yahoo.com logoNovartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study (NYSE:NVS)
finance.yahoo.com - September 23 at 11:13 AM
News IconDoes Novartis AG (NVS) Have The Solution For Malaria? (NYSE:NVS)
feedproxy.google.com - September 22 at 1:26 PM
marketexclusive.com logoDoes Novartis AG (NYSE:NVS) Have The Solution For Malaria? - Market Exclusive (NYSE:NVS)
marketexclusive.com - September 22 at 11:19 AM
News IconActive Stocks Need to Consider- Novartis AG (NYSE:NVS), Calix Inc. (NYSE:CALX), Medovex (NASDAQ:MDVX) - Seneca Globe (NYSE:NVS)
www.senecaglobe.com - September 21 at 10:37 AM
News IconNovartis' MS hopes expand after positive trial (NYSE:NVS)
magseriesusa.net - September 20 at 11:45 AM
wsj.com logoGlaxoSmithKline Names Emma Walmsley as Next Chief Executive (NYSE:NVS)
www.wsj.com - September 20 at 11:45 AM
benzinga.com logoNovartis A Buy At Chardan (NYSE:NVS)
www.benzinga.com - September 20 at 11:45 AM
fidaily.com logoChardan Capital Initiates Coverage on Novartis AG Common Stock (NVS) Setting A Rating Of “Buy” (NYSE:NVS)
www.fidaily.com - September 20 at 11:45 AM
thecountrycaller.com logoNovartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope (NYSE:NVS)
www.thecountrycaller.com - September 20 at 11:45 AM
finance.yahoo.com logoBreaking the mould: GSK picks Big Pharma's first female CEO (NYSE:NVS)
in.finance.yahoo.com - September 20 at 11:45 AM
News IconStocks Rallying on Glossy Earnings: Mylan N.V. (NASDAQ:MYL), Novartis AG (NYSE:NVS) - Street Wise Report (press release) (blog) (NYSE:NVS)
streetwisereport.com - September 19 at 6:29 PM
News IconCan Novartis AG (ADR) (NVS) Survive with Alcon Crisis? - Smаrt Stоck Nеws (NYSE:NVS)
www.smartstocknews.com - September 19 at 6:29 PM
thecountrycaller.com logoNovartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope - TCC (NYSE:NVS)
www.thecountrycaller.com - September 19 at 6:29 PM
finance.yahoo.com logoNovartis (NVS) Presents Positive Data on Cardiovascular Drug (NYSE:NVS)
finance.yahoo.com - September 19 at 11:00 AM
investopedia.com logoAMGN: How Amgen's Stock Price Rose 18.55% in 6 Months (NYSE:NVS)
www.investopedia.com - September 17 at 10:57 AM
finance.yahoo.com logoNovartis Reports Positive Phase II Data on Migraine Drug (NYSE:NVS)
finance.yahoo.com - September 16 at 10:00 AM
News IconAperio Group LLC Decreased Stake in Novartis Ag Sponsored ... - Chester News (NYSE:NVS)
www.chesterindependent.com - September 15 at 9:57 AM
News IconHealth care stocks (NYSE:NVS)
www.dlnnews.com - September 14 at 6:36 PM
marketrealist.com logoGSK Optimistic about Future of Its Consumer Healthcare Segment (NYSE:NVS)
marketrealist.com - September 13 at 11:24 AM
marketrealist.com logoWhat’s the Problem with GSK’s Pharmaceutical Segment? (NYSE:NVS)
marketrealist.com - September 12 at 11:05 AM
marketrealist.com logoHow Can Pfizer Revive Its Essential Health Business? (NYSE:NVS)
marketrealist.com - September 12 at 11:05 AM
nasdaq.com logoNovartis: Alcon, TrueVision 3D Launch NGENUITY 3D Visualization System (NYSE:NVS)
www.nasdaq.com - September 8 at 6:15 PM
News IconActive Stocks in 'How' and 'Why'- Novartis AG (NYSE:NVS), Biomerica Inc. (NASDAQ:BMRA), Inphi Corporation (NYSE ... - Seneca Globe (NYSE:NVS)
www.senecaglobe.com - September 8 at 10:19 AM
finance.yahoo.com logoEurope: New safe haven? (NYSE:NVS)
finance.yahoo.com - September 7 at 6:39 PM
News IconPost Earnings Coverage as Cooper Cos Earnings Grows 97 Percent (NYSE:NVS)
news.investornetwork.com - September 7 at 10:03 AM
finance.yahoo.com logoGretchen Carlson's $20 Million And Some Of The Biggest Sexual Harassment Payouts Ever (NYSE:NVS)
finance.yahoo.com - September 6 at 6:40 PM
finance.yahoo.com logo2:49 am Novartis reports new data from FLAME study confirming Ultibro Breezhaler more effective than Seretide (NYSE:NVS)
finance.yahoo.com - September 6 at 11:13 AM
finance.yahoo.com logoNovartis (NVS) Reports Positive Data on Ultibro Breezhaler (NYSE:NVS)
finance.yahoo.com - September 6 at 11:13 AM
thecountrycaller.com logoThe Biosimilar of Amgen's Enbrel, by Novartis AG (ADR) (NYSE:NVS), has been approved by FDA - TCC (NYSE:NVS)
www.thecountrycaller.com - September 2 at 11:21 AM
News IconTop Earnings to Watch for: Novartis AG (NYSE:NVS) - The Voice Registrar (NYSE:NVS)
voiceregistrar.com - September 2 at 11:21 AM
News IconTrending Stock - Novartis AG's (NVS) - Hot Stocks Point (NYSE:NVS)
www.hotstockspoint.com - September 2 at 11:21 AM
marketexclusive.com logoWhat Signal Is Novartis AG (NYSE:NVS) Sending Out With Its Cell Therapy Move? - Market Exclusive (NYSE:NVS)
marketexclusive.com - September 2 at 11:21 AM
News IconJuno, Kite Pharma Fall After Novartis Dissolves CAR-T Unit (NYSE:NVS)
www.pharmalive.com - September 1 at 6:28 PM
News IconNovartis to Dissolve Cell and Gene Therapy Unit (NYSE:NVS)
www.pharmalive.com - September 1 at 9:41 AM
marketexclusive.com logoWhat Signal Is Novartis AG (NYSE:NVS) Sending Out With Its Cell Therapy Move? (NYSE:NVS)
marketexclusive.com - September 1 at 9:41 AM
bloomberg.com logoNovartis Rings Another Cell-Therapy Alarm Bell (NYSE:NVS)
www.bloomberg.com - September 1 at 9:41 AM
News IconBlog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgens Enbrel (NYSE:NVS)
news.investornetwork.com - September 1 at 9:41 AM
thecountrycaller.com logoNovartis AG (ADR) (NVS) Fights for Survival after Patent Expiration (NYSE:NVS)
www.thecountrycaller.com - August 31 at 11:32 AM
wsj.com logoFDA Approves Novartis’s Biosimilar to Amgen’s Enbrel (NYSE:NVS)
www.wsj.com - August 31 at 11:32 AM
finance.yahoo.com logoNovartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel (NYSE:NVS)
finance.yahoo.com - August 31 at 11:32 AM
marketexclusive.com logoNovartis AG (ADR) (NYSE:NVS) Says A Picture Is Worth A Thousand Words (NYSE:NVS)
marketexclusive.com - August 31 at 11:32 AM
thecountrycaller.com logoNovartis AG (NYSE:NVS) Fights for Survival after Patent Expiration - TCC (NYSE:NVS)
www.thecountrycaller.com - August 30 at 6:30 PM
sg.finance.yahoo.com logoNovartis wins US OK for biosimilar version of Amgen's Enbrel (NYSE:NVS)
sg.finance.yahoo.com - August 30 at 6:29 PM

Social

Novartis AG (NYSE:NVS) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff